HIV and ID Observations

June 12th, 2025

Why the Sudden Firing of ACIP Members Should Put Every Clinician on High Alert

There are certain irrefutable verities when, like me, you’re an infectious diseases specialist married to a pediatrician. Here are our top two, which are deeply interrelated: Infectious deaths in children, or severe illnesses that lead to lifelong disability, are more devastating than similar events in adults. Each such case in a baby or child is […]

---

June 6th, 2025

How ID Doctors Get Paid, Part 3: The Grab Bag Edition

If you’ve made it this far, congratulations! You’re now deep into the ID Reimbursement Rabbit Hole. Part 1 and Part 2 covered how ID doctors contribute immense value through patient care, stewardship, infection control, travel clinics — proudly fighting along the way for appropriate compensation as the “Loss Leaders” of the hospital. (Did you get your […]

---

May 31st, 2025

How ID Doctors Get Paid, Part 2: Infection Control and Other Invaluable (but Often Invisible) Work

Before getting to today’s main topic, allow me a brief protest — three recent vaccine-related actions that reek of profound (and misguided) vaccine distrust from HHS leadership. They are: Cancellation of a grant to develop an H5N1 vaccine. Preparation for this looming pandemic threat is critical, and there’s arguably no better way than having a vaccine ready. […]

---

May 22nd, 2025

The Pros and Cons of the Latest FDA Actions on COVID Vaccines

In case you missed it, last week the FDA granted full approval for the Novavax COVID-19 vaccine. This vaccine, which uses a more traditional protein-plus-adjuvant strategy instead of the mRNA approach of Pfizer and Moderna, is no longer in “Emergency Use Authorization (EUA)” limbo. Here’s what that means in practical terms: It shows the data the company […]

---

May 18th, 2025

How ID Doctors Get Paid — The Bread, Butter, and Budget Deficits of Infectious Diseases

Two decades ago, Dr. Atul Gawande wrote a memorable piece for The New Yorker about how doctors in the United States get paid. Providing a nice mix of self-reflection about his own experience and some skillful reporting, he described the challenging process of figuring out what he, a newly hired surgeon, should earn for a salary. […]

---

May 7th, 2025

FDA’s Latest Appointment Is … Interesting

Those of us who follow infectious diseases and vaccine science closely (OK, obsessively) know that the FDA’s Center for Biologics Evaluation and Research (CBER) plays an enormous role in public health. Vaccines, gene therapies, monoclonal antibodies, blood products — all pass through CBER on their path to approval. During the COVID-19 pandemic, this center became […]

---

April 30th, 2025

On-Service ID Link-o-Rama — Osmosis Edition

First-year ID fellows this time of year bring a lot to inpatient consult rotations. Years of high-volume inpatient care have sharpened their clinical instincts, and at this point they have an impressive fund of ID knowledge. Plus, the fellow on our current rotation gets along great with everyone — patients and consulting clinicians alike — […]

---

April 18th, 2025

SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia

For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultations — and for good reason: when mismanaged or complicated, it can lead to high morbidity, a myriad of complications, and a disturbingly high mortality rate. Despite its clinical […]

---

April 11th, 2025

Looking Back at a Defunct ID Meeting — and Ahead to a Thriving One

Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising “bug-drug” studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, […]

---

April 3rd, 2025

Gepotidacin — New Antibiotic or Rare Tropical Bird?

Imagine you’re birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly: Look, it’s the elusive Blujepa! A rare sighting! No, not a real bird, but the brand name of gepotidacin, something rarer — and arguably more exciting — than […]

---